PL444462A1 - Sposób oceny chemiowrażliwości komórek nowotworowych in vitro na leki przeciwnowotworowe i sposób diagnostyki ex vivo nowotworu piersi - Google Patents

Sposób oceny chemiowrażliwości komórek nowotworowych in vitro na leki przeciwnowotworowe i sposób diagnostyki ex vivo nowotworu piersi

Info

Publication number
PL444462A1
PL444462A1 PL444462A PL44446223A PL444462A1 PL 444462 A1 PL444462 A1 PL 444462A1 PL 444462 A PL444462 A PL 444462A PL 44446223 A PL44446223 A PL 44446223A PL 444462 A1 PL444462 A1 PL 444462A1
Authority
PL
Poland
Prior art keywords
assessing
anticancer drugs
breast cancer
cancer cells
vivo diagnosis
Prior art date
Application number
PL444462A
Other languages
English (en)
Inventor
Dariusz PAWLAK
Anna TANKIEWICZ-KWEDLO
Krystyna PAWLAK
Bogumiła Czartoryska-Arłukowicz
Leszek KOZŁOWSKI
Tomasz ŁOBACZ
Mariusz KODA
Original Assignee
Uniwersytet Medyczny W Białymstoku
Białostockie Centrum Onkologii Im. M. Skłodowskiej-Curie W Białymstoku
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Medyczny W Białymstoku, Białostockie Centrum Onkologii Im. M. Skłodowskiej-Curie W Białymstoku filed Critical Uniwersytet Medyczny W Białymstoku
Priority to PL444462A priority Critical patent/PL444462A1/pl
Priority to PCT/IB2024/053727 priority patent/WO2024218665A1/en
Publication of PL444462A1 publication Critical patent/PL444462A1/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Przedmiotem wynalazku jest sposób oceny chemiowrażliwości komórek nowotworowych in vitro na leki przeciwnowotworowe przed włączeniem ich do terapii konkretnego pacjenta onkologicznego, określany przez twórców wynalazku jako Oncochem-Test. Kolejnym przedmiotem wynalazku jest sposób diagnostyki ex vivo nowotworu piersi.
PL444462A 2023-04-18 2023-04-18 Sposób oceny chemiowrażliwości komórek nowotworowych in vitro na leki przeciwnowotworowe i sposób diagnostyki ex vivo nowotworu piersi PL444462A1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL444462A PL444462A1 (pl) 2023-04-18 2023-04-18 Sposób oceny chemiowrażliwości komórek nowotworowych in vitro na leki przeciwnowotworowe i sposób diagnostyki ex vivo nowotworu piersi
PCT/IB2024/053727 WO2024218665A1 (en) 2023-04-18 2024-04-17 Method for in vitro assessment of the chemosensitivity of neoplastic cells to antineoplastic drugs and method for ex vivo diagnostics of breast neoplasm

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL444462A PL444462A1 (pl) 2023-04-18 2023-04-18 Sposób oceny chemiowrażliwości komórek nowotworowych in vitro na leki przeciwnowotworowe i sposób diagnostyki ex vivo nowotworu piersi

Publications (1)

Publication Number Publication Date
PL444462A1 true PL444462A1 (pl) 2024-10-21

Family

ID=91954018

Family Applications (1)

Application Number Title Priority Date Filing Date
PL444462A PL444462A1 (pl) 2023-04-18 2023-04-18 Sposób oceny chemiowrażliwości komórek nowotworowych in vitro na leki przeciwnowotworowe i sposób diagnostyki ex vivo nowotworu piersi

Country Status (2)

Country Link
PL (1) PL444462A1 (pl)
WO (1) WO2024218665A1 (pl)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013050962A1 (en) * 2011-10-04 2013-04-11 Mitra Biotech Private Limited Ecm composition, tumor microenvironment platform and methods thereof
CN110373445A (zh) * 2019-06-21 2019-10-25 南通大学 一种抗肿瘤药物快速药效测试试剂盒的制备方法及使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009509171A (ja) * 2005-09-21 2009-03-05 シーシーシー ダイアグノスティックス， エルエルシー 個別化抗癌化学療法（ｐａｃ）のための包括的な診断試験
IL269821B2 (en) * 2017-04-05 2024-02-01 Yeda Res & Dev In vitro culture system and methods for its use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013050962A1 (en) * 2011-10-04 2013-04-11 Mitra Biotech Private Limited Ecm composition, tumor microenvironment platform and methods thereof
CN110373445A (zh) * 2019-06-21 2019-10-25 南通大学 一种抗肿瘤药物快速药效测试试剂盒的制备方法及使用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PELIZZARI, G. ET AL.: "Cancers 2019, 11, 1243, doi: 10.3390/cancers11091243", "LACTATE DEHYDROGENASE (LDH) RESPONSE TO FIRST-LINE TREATMENT PREDICTS SURVIVAL IN METASTATIC BREAST CANCER: FIRST CLUSES FOR A COST-EFFECTIVE AND DYNAMIC BIOMARKER" *

Also Published As

Publication number Publication date
WO2024218665A1 (en) 2024-10-24

Similar Documents

Publication Publication Date Title
AR076197A1 (es) Regimen de tratamiento que utiliza neratinib para cancer de mama
BR112019018685A8 (pt) Anticorpos, composição farmacêutica, kit, usos de um anticorpo e método in vitro de identificação ou seleção de um anticorpo
Qu et al. IL-7/IL-7 receptor axis stimulates prostate cancer cell invasion and migration via AKT/NF-κB pathway
EA201290138A1 (ru) Производные пиразола как модуляторы кальциевых каналов, активируемых высвобождением кальция
MX362514B (es) Kits y ensayos de diagnostico para la deteccion del receptor 1 de folato.
BR112016007864A2 (pt) método para a prognose e tratamento de metástase de câncer
AR083357A1 (es) Metodo para el diagnostico, pronostico y tratamiento de la metastasis de cancer de mama
BR112014004336A2 (pt) sistema e método para estimar a quantidade de interesse de um sistema de artéria / tecido / veia dinâmico
EA201792447A1 (ru) Способы и композиции для диагностики и лечения заболеваний у пациентов, имеющих повышенные уровни cxcl9 и других биомаркеров
MX2021009247A (es) Metodos, sistemas y kits para tratar enfermedades inflamatorias que se dirigen a il18r1.
AR115566A1 (es) Composiciones y procedimientos para el tratamiento del cáncer
BR112013003793A2 (pt) método de diagnóstico das doenças neurodegenerativas
BR112015015574A2 (pt) método e sistema de diagnóstico e monitoramento de exame cardiovascular
ES2570609T3 (es) Método para someter a ensayo la aminoacilasa 1 para el diagnóstico in vitro del cáncer colorrectal
Falasca et al. Cannabinoids and cancer
AR089833A1 (es) Biomarcador predictivo para el tratamiento del cancer con anticuerpos de adcc incrementada
Barinoff et al. Improvement of survival in patient with primary metastatic breast cancer over a 10-year periode: prospective analyses based on individual patient date from a multicenter data bank
RU2013140122A (ru) Способ диагностики рака молочной железы
WO2022130433A3 (en) Method for in vitro diagnosis of mucositis in cancer patients undergoing antitumor therapy
AWARDS HIGHLIGHTS OF THE NCCN 2022 ANNUAL CONFERENCE
Gamal et al. Accelerated Chemoradiation vs. Conventional Chemoradiation in Locally Advanced Head and Neck Cancer: A Retrospective Study.
Skala et al. Imaging cellular metabolic heterogeneity in cancer
Crown et al. Extreme Oncoplastic Breast Conserving Surgery: Can We Reduce Rates of Mastectomy and Chemotherapy Use?
MX2024011525A (es) Anticuerpo zip12.
UA42973U (ru) Способ клинического окклюзионного анализа